echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Quotation analysis and 8-point in-depth thinking on the second round of national belt purchase (attached with the price chart of the selected products)

    Quotation analysis and 8-point in-depth thinking on the second round of national belt purchase (attached with the price chart of the selected products)

    • Last Update: 2020-01-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today (January 17, 2020) morning, the author, as a spectator, witnessed the ups and downs of various varieties of national volume procurement at No 1800 Tianshan Road Please refer to the official data for relevant bid winning and dropping (attached at the end of the paper: relevant data analysis of bid winning and dropping of the second batch of national volume procurement related varieties), for your reference According to the on-the-spot information, for example, the product of candesartan oral regular release dosage form, 8mg14 tablets, Yongning, Zhejiang, has quoted a price of 3.69 yuan, only 0.26 yuan for each tablet, which is relative to the lowest price in 2019 of 1.88 yuan, with a drop of 86%! In the bidding of glimepiride tablets (1mg), the price offered by Chongqing kangkeri Pharmaceutical Co., Ltd was 0.053 yuan / tablet; Sanofi, the original research group, gave up the price Tadalafei, Qilu, Nanjing Tianqing and Lilai were not selected, and Tianshi and Haiyue were basically selected with 42.4 yuan and 47.0304 yuan In the bidding of albumin paclitaxel, Hengrui, Shiyao, Qilu and Xinji were quoted at 780 yuan, 747 yuan, 1828 yuan and 1150 yuan / piece respectively Qilu was very sorry to lose the bid Acarbose, Huadong, LVYE and Bayer have quoted prices of 13.96 yuan, 9.6 yuan and 5.42 yuan respectively, and Bayer's single-chip price is 0.1807 yuan No surprise, Huadong will be out The author will describe the bidding results in detail here In fact, it is of little significance to discuss how to win the bid and how to abandon the bid I just want to share eight aspects of the experience of the national procurement with volume: first, comply with the policy After the 4 + 7 and combined mining expansion, the enterprises have gradually calmed down from the original panic, loss, tension and anxiety, and become more calm Since the new situation determines the new normal, they can't go against the trend, the policy can't be changed, they can only change themselves 2、 There are 160 varieties of generic drugs that have been evaluated and are hopeless in the next three years It's estimated that there will be another two years or so The major varieties in key fields will be listed Those who have won the bid through evaluation will seize the market that has not won the bid through evaluation, and those who have won the bid through evaluation will seize the market that has not been evaluated, and those who have won the bid through evaluation will not be alone in the generic drugs in the same treatment field As soon as one year, or as slowly as three years, generic drugs that have been evaluated hopelessly in the same field of treatment may gradually accept the situation that the market is being eroded Faced with policy orientation and medication habits, how many opportunities can a pen on the clinical front line give these generic drugs? 3、 The centralized purchase policy should be properly adjusted to prevent the occurrence of God operation policy The enterprises that actively participate in the consistency evaluation should be given appropriate support, and the positive guidance should completely eliminate the concerns, so as to avoid the situation that good and bad coins become bad coins together 4、 The killer of ending the high price bullying of original research drugs is to promote consistency evaluation with volume procurement to improve the quality of generic drugs, which is the core policy of import substitution Only by improving the quality can it be replaced effectively, so that the people can finally trust the domestic medicine In order to achieve this goal, there are at least seven to eight years to go before the centralized purchase of drugs, and at least five to six kinds of tricks No matter how smoothly the trade friction is solved, it is still the first thing for Chinese people to do well in their own affairs! History tells us that only when we carry forward the "saying comes to saying, doing comes to doing" to the extreme, can we truly reach the state of "unity of words and deeds" To solve the burden of high price bullying of original research drugs in the pharmaceutical market immediately, it is the duty of drug collection 5、 The future market belongs to the capable, powerful and determined enterprises in the Chinese market, which can only be the world of innovative drugs + over rated generic drugs Whoever has the ability will rise to create new drugs, who has the strength will have the experience of evaluating generic drugs, and who has the determination will play the ordinary generic drugs to the extreme Enterprises that have neither the ability nor the strength nor the fixed force can only disappear in the vast red sea 6、 A few speculative enterprises should be forbidden to rush to the market price competition with low price blindfold, and the bottom line should be set from the perspective of policy-making, rather than with some enterprises blindfold When these speculators disturb the market for some reason and have no way out, how many of them will stick to that moment? 7、 Replace the patient's interests of "one province, one source of goods" with "one province, many centers" Can consistency assessment be the bottom line of quality? From this background, should the future market division mechanism be adjusted? It is suggested that the current single source of goods in a province should be adjusted to more than one province, and then the enterprises winning the bid at the lowest price can enjoy a larger share of the province, and the enterprises winning the bid at the second lowest price can enjoy the second largest share In other words, this can not only fully guarantee the needs of each patient level in a province, but also prevent a province from eating the original research, B province can only eat the evaluated generic drugs, and a province has patients In order to buy medicine, we have to rush across provinces 8、 It's very important to think about the medical situation Economic development is a steady and positive trend In this context, medical insurance funds can only be used on the cutting edge and spend money on savings The way out for foreign companies is to sell new drugs, and the way out for domestic generic drugs is to replace the original research and make money through evaluation With the money saved, the government will increase the proportion of patients' reimbursement and support the development of innovative enterprises Under such a clear path, every enterprise really needs to think about where to go Don't be too happy to win the bid, and don't be sad to lose the bid Pharmaceutical companies don't need to be so pessimistic and confused They just used to live a comfortable life or adapt to it Now they suddenly change and feel uncomfortable The drug price is unreasonably high This time, we will go straight to the low price and eliminate the difference between middlemen It is good for patients, medical insurance and even enterprises There is no doubt that the relevant policies of one round of 4 + 7 and two rounds of national procurement with volume have been issued after careful consideration With the development of the times and the rapid development of medicine, it is the mission of the pharmaceutical industry and the responsibility of every medical practitioner to let the public enjoy the progress of modern technology and get better therapeutic effect with better cost performance Let enterprises realize rational and fair competition, let doctors see doctors from the reality, let patients calmly rational consumption, let the pharmaceutical industry continue to upgrade steadily! This is a trend that must be seen carefully Appendix: the second batch of national procurement related varieties won the bid and lost the bid (for reference only) listen to the white statement: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.